Great Novel Therapeutics Biotech & Medicals
7427
Rank in Stocks
#19843
Great Novel Therapeutics Biotech & Medicals specializes in crafting... Great Novel Therapeutics Biotech & Medicals specializes in crafting pharmaceutical solutions to combat advanced and treatment-resistant cancers. Their primary focus lies in the realm of cancer immunotherapy, encompassing the creation of compounds such as tumor microenvironment regulators, epigenetic immunoactivators, and immune-regulating multi-kinase inhibitors. The company was previously known as GNT Biotech & Medicals Corporation. Established in 2013, its headquarters are situated in Taipei City, Taiwan.
Share Price
$1.82
Last synced: 2026-11-10
Market Cap
$96.46M
Change (1 day)
-0.33%
Change (1 year)
52.71%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Great Novel Therapeutics Biotech & Medicals (7427)
Category
Healthcare
EPS for Great Novel Therapeutics Biotech & Medicals (7427)
EPS as of June 2026 TTM: $-0.08
According to Great Novel Therapeutics Biotech & Medicals's latest financial reports, its current EPS (TTM) is $-0.08. At the end of 2025 the company had an EPS of $-0.07, an increase over its 2024 EPS of $-0.08.
EPS history for Great Novel Therapeutics Biotech & Medicals from 2013 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.08 | 8.43% |
| 2025 | $-0.07 | -11.84% |
| 2024 | $-0.08 | 40.25% |
| 2023 | $-0.06 | -26.43% |
| 2022 | $-0.08 | 22.84% |
| 2021 | $-0.06 | -12.55% |
| 2020 | $-0.07 | -4.63% |
| 2019 | $-0.07 | -18.24% |
| 2018 | $-0.09 | -51.06% |
| 2017 | $-0.18 | 92.15% |
| 2016 | $-0.10 | -15.40% |
| 2015 | $-0.11 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -20,732.41% |
US
|
|
| $-7.07 | 9,214.89% |
US
|
|
| $-5.29 | 6,869.70% |
AU
|
|
| $12.88 | -17,069.83% |
BE
|
|
| $21.56 | -28,505.80% |
NL
|
Questions about Great Novel Therapeutics Biotech & Medicals's earnings per share (EPS)
What is Great Novel Therapeutics Biotech & Medicals's earnings per share (EPS)?
Great Novel Therapeutics Biotech & Medicals's earnings per share (EPS) over the last twelve months is $-0.08, as of Jun 2026.
What was Great Novel Therapeutics Biotech & Medicals's earnings per share (EPS) in 2025?
In 2025, Great Novel Therapeutics Biotech & Medicals's earnings per share (EPS) was $-0.07, compared with $-0.08 in 2024.
How has Great Novel Therapeutics Biotech & Medicals's earnings per share (EPS) changed since 2020?
From 2020 to 2025, Great Novel Therapeutics Biotech & Medicals's earnings per share (EPS) was highest in 2023 ($-0.06) and lowest in 2024 ($-0.08).
How does Great Novel Therapeutics Biotech & Medicals's earnings per share (EPS) compare with similar companies?
Great Novel Therapeutics Biotech & Medicals's earnings per share (EPS) ($-0.08) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.